The tide of springs has set in motion a new course and has done its part. 24 february is the first working day after the festivalTianjinShen shwe pharmaceuticals ltd. (hereinafter referred to as " tianjin " )Research and developmentThe center is already busy. In front of the laboratory of the new medicines discovery department, researchers are conducting target-to-molecule screening using organ-type platforms; in the laboratory of the department of pharmacy, research and development staff are busy debugging compositers to prepare for process research; and in the analysis laboratory, several liquid chromatographs are in operation and samples are being tested in an orderly manner。
It's a vivid reflection of the return to work after shinshinBiomedicineIn the form of a “preliminary war, start-up and sprint”, the enterprise struggled to attack the true picture of the “open-door red” for a quarter. As an enterprise focusing on the development and production of oncological drugs, tien jin-shin swe is currently carrying forward several research and development projects simultaneously。
“we have one of the most rapidly developing therapeutic drugs, and the project team is making every effort to accelerate the pace of related research. The pharmacological process is complex, quality control requirements are stringent, and the research and development team maintains online discussions throughout the spring season, continuously advancing the documentation and programme development process, and, at the first hour of the festival, is engaged in intensive work to achieve a phased breakthrough in the first quarter.” the director of the drug project described the ongoing refinement of technical information, the advancement of process optimization and quality studies, and the initiation of preparations at the production site。
At the same time, the company pressed the "quick-in" key on the construction of the production base. To match r & d progress and meet the futureIndustryIn response to demand, tianjin swe is accelerating the construction of production facilities to lay the foundation for the subsequent transformation of product outcomes。
General manager guo fei-ho of tianjin heung-seo said, "this year is the beginning of the 15th year, and we will ensure that the work is advanced in a good quality in the first quarter of the year, aiming to achieve multiple breakthroughs in research and development for tumorsInnovationThe pharmaceutical research and development industry contributes.”
On the same day, as a leading company in the field of innovative vaccines, the research team in charge of clinical operations of concino biology inc. (hereinafter referred to as concino biology) gathered early in the office to assess the progress made in the implementation of clinical trials and to make every effort to promote the high-quality landing of clinical research abroad。
Innovation drives results and industrial development adds energy. In the first half of 2025, concino's biologically autonomously developed infant and young children were successfully tested in the national drug review centre of the national drug regulatory authority for the use of 100 (assembly) cytological combination vaccines; in the second half of the year, the 13-priced pneumocococcal multi-sugar combination vaccine, developed by the company, was distributed to domestic and overseas markets respectively。
The chairman and chief executive officer of concinón biologicals, kung fu, stated that the successful listing of yopeshin and man haehin's “off to sea” would provide solid support for building a national immunization barrier. After the spring break, business blocks were quickly invested in key tasks such as steady supply of priority products, speed-up of core r & d projects, internationalized layout expansion, anchoring annual targets and working towards high-quality development throughout the year。
The biopharmaceuticals industry, a strategic and emerging industry supported by the state as a priority, is an important player and a key development orientation for tianjin manufacturing cities. The city has given high priority to industrial development, led by the city science and technology bureau, which has set up a workshop on the development of the biomedicine industry, which brings together the various functional sectors, launched a full chain of support for industrial development policies, made it possible to block the air transport of radioactive drugs, set up a joint regulatory mechanism for special items of high risk, and promoted the effectiveness of support policies. By 2025, our city's biomedicine industry was worth more than $10. 6 billion, an increase of about 10 per cent over the same period. The industry continued to grow in size, its core competitiveness steadily increased and it achieved good quality development。
In an effort to sustain the acceleration of the biomedicine industry and work towards a quarterly “open-door red”, the city science and technology bureau indicated that a set of “packages” would be put in place to promote high-quality industrial development. The preparation of the “fifty five” plan for the development of the bio-manufacturing and bio-medicine industries in tianjin city has been accelerated, the planning content has been continuously improved and the stock of priority projects for adaptation has been increased, and a programme for the construction of landmark specialty parks has been developed with the districts. In conjunction with the industrial chain layout, special support policies have been put in place to streamline the two main chains of biomedicine, biomanufacturing and six sub-chains of chemicals, biopharmaceuticals, etc., and to implement a “one-size-fits-all” service. Specific policies have been developed at the municipal and district levels in the area of brain interfaces, with a view to revising specific policies in the field of biological manufacturing, as well as in the drafting of specific policies in the field of medical equipment by the municipal drug inspectorate。
At the same time, the biomedicine industry development task force has been working in tandem to deepen the one-stop service system of the enterprise-system-sector, to provide priority business interfaces, efficiently solve business development challenges and continue to build confidence in business development. Full-service and nord's series of solid investment projects in zin was successfully implemented, facilitating the early completion of the project and its early delivery, continuing to support the clinical application of the enterprise's innovative products in zin, and attracting more products from the enterprise headquarters to be distributed and produced in tianjin. Actively seeking to increase support for the development, production and sale of natural resources, accelerating the process of research and development of new products, and increasing the market share of natural resources in retail terminals and medical terminals through a strong commercial network of chinese medicine。
The project is the lifeline for industrial development and the recruitment of businesses is the driving force behind industrial growth。
The chief of the biomedicine division of the city department of science and technology, zhang xian wei, indicated that the next phase of the development of the biopharmaceutical industry would focus on project construction: the ongoing projects for the service of kelleyin, “project for the testing and industrialization of high-end formulations”, “project for the rapid preparation of the car-t drug and for the development and industrialization of a universal platform”, which were planned to be completed; the new projects for the biti medical centre, “northern china innovation centre”, and the second phase of the project for the integration of phare materials and formulations, were to be started on schedule to generate additional quantities for industrial development; and the active promotion of projects such as the “model engineering project for the industrialization of tons of micro-organisms”, the “new generation of the brain river laboratory” and the “network for the support of technological innovation and industrial services for a new generation of brain interfaces”, which would help our city to take the lead role in future industrial development。
In the case of industrial firms, the programme for the development of the bio-pharmaceutical industry is based on a coordinated approach, which combines resource endowments and specialty industry layouts in each district, with a view to facilitating the early registration of projects. In the lead-up to the competition, the headquarters of the company is actively engaged in developing panels and developing innovative products in zimbaki; in the new arenas around cells and gene therapy, nucleic acids and brain-engineer interfaces, thanks to our city's specialty park carriers, more innovative small and medium-sized enterprises are being hatched; and in the special arenas around bio-manufacturing and radioactive drugs, the international centre for science, technology and innovation in beijing (icit) has been actively engaged in building outreach opportunities to take over the innovations and industrial projects of biomedicine in beijing and attract more beijing projects for transformation。
